Trial · NCT07889154
Physical Activity, Sleep Quality, and Respiratory Function in Obstructive Sleep Apnea
NCT07889154, Not applicable, Recruiting, Medipol University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Physical Activity, Sleep Quality, and Respiratory Function in Obstructive Sleep Apnea. Trials, record NCT07889154. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07889154
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Physical Activity, Sleep Quality, and Respiratory Function in Obstructive Sleep Apnea
- NCT number
- NCT07889154
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 48 participants, estimated
- Lead sponsor
- Medipol University
- Conditions
- Obstructive Sleep Apnea, Sleep Quality, Respiratory Function
- Interventions
- Physical Activity Education
- First posted
- 2026-10-22
- Last updated
- 2026-10-27
Source ClinicalTrials.gov
Registered outcomes21
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Pittsburgh Sleep Quality Index (PSQI) | 0.,12., and 24. weeks | A 19-item self-report questionnaire assessing sleep quality and disturbances over the previous month, including sleep duration, latency, efficiency, and daytime dysfunction. Total scores range from 0 to 21, with higher scores indicating poorer sleep quality. Scores above 5 indicate poor sleep quality. |
| Primary | Average Nightly CPAP Usage | 0., and 24. weeks | Average duration of continuous positive airway pressure (CPAP) use per night, measured in hours per night using data downloaded from the CPAP device. The average nightly usage will be calculated over the device-data assessment period. Good adherence will be defined as CPAP use for at least 4 hours per night on at least 5 nights per week. |
| Primary | Average CPAP Mask Leak | 0., and 24. weeks | Average mask leak during CPAP use, assessed using data downloaded from the CPAP device over the device-data assessment period. Mask leak will be reported using the unit provided by the device (L/min). Good adherence will be defined as CPAP use for at least 4 hours per night on at least 5 nights per week. |
| Primary | Average CPAP Treatment Pressure | 0., and 24. weeks | Average treatment pressure during CPAP use, assessed using data downloaded from the CPAP device over the device-data assessment period. Treatment pressure will be reported using the unit provided by the device (cm H2O). Good adherence will be defined as CPAP use for at least 4 hours per night on at least 5 nights per week. |
| Primary | MIP-MEP measurement | 0.,12., and 24. weeks | In centimeters of water (cmH2O), it will be obtained using a Respiratory Muscle Strength Measurement Device-MIP-MEP (MD Diagnostics Ltd., RP Check, United Kingdom) in accordance with the recommendations of the American Thoracic Society. |
| Primary | Forced Vital Capacity (FVC) measurement | 0.,12., and 24. weeks | It is the amount of air expelled after maximum inspiration following a normal breath, expressed in liters. While healthy individuals can forcefully exhale air for 2-3 seconds, this time can be as short as 10-15 seconds for individuals with airway problems. At the end of the test, the expected reference value should be between 80-120%. This will be performed using a spirometer (Cosmed, Pony FX, Italy). The best forced vital capacity (FVC) maneuver from at least 3 attempts will be selected according to the criteria of the American Thoracic Society. To perform the spirometric maneuvers, participants will sit upright with their feet on the floor and the nose clip correctly positioned. |
| Primary | FEV₁ (Forced Expiratory Volume in 1 Second) | 0.,12., and 24. weeks | It is the volume of air exhaled in the first second after forced expiration. Although measured in liters, it actually indicates the airflow rate. In healthy individuals, at least 72% of the air should be exhaled, reflecting the function of the large airways. This will be performed using a spirometer (Cosmed, Pony FX, Italy). To perform the spirometric maneuvers, participants will sit upright with their feet on the floor and the nose clip correctly positioned. |
| Primary | FEV1/FVC ratio | 0.,12., and 24. weeks | This ratio is obtained by dividing FEV1 by FVC and evaluates airway patency and lung function. In a normal individual, this ratio is around 70-80%. This will be performed using a spirometer (Cosmed, Pony FX, Italy). To perform the spirometric maneuvers, participants will sit upright with their feet on the floor and the nose clip correctly positioned. |
| Primary | FEF 25%-75% (Maximal Mid-Expiratory Flow Rate | 0.,12., and 24. weeks | It refers to the average airflow rate during forced expiration, when 25% to 75% of the volume is expelled. It is measured in liters per second. It reflects the function of the medium and small airways. A value above 80% of the reference value is normal. This will be performed using a spirometer (Cosmed, Pony FX, Italy). To perform the spirometric maneuvers, participants will sit upright with their feet on the floor and the nose clip correctly positioned. |
| Primary | Baecke Habitual Physical Activity Questionnaire (BHPAQ) | 0.,12., and 24. weeks | The Baecke Habitual Physical Activity Questionnaire (BHPAQ) is a 16-item self-report questionnaire assessing habitual physical activity over the previous 12 months across three domains: occupational physical activity (8 items), sports physical activity (4 items), and leisure-time physical activity (4 items). The total score is calculated by summing the scores of the three domains. The total score ranges from 3 to 15, with higher scores indicating higher levels of habitual physical activity and a better outcome. |
1 to 10 of 21Source ClinicalTrials.gov
See all 21 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07889154
GET https://conductscience.org/api/trials/v1/NCT07889154/registered?page=2